Early Access

10-QPeriod: Q3 FY2009

Cencora, Inc. Quarterly Report for Q3 Ended Jun 30, 2009

Filed August 6, 2009For Securities:COR

Summary

Cencora, Inc. (COR) reported its second quarter fiscal year 2009 results, demonstrating resilience and growth in a challenging economic environment. Total revenue saw a modest 2% increase year-over-year, driven by new customer acquisitions and strong performance in its specialty group (ABSG), which more than offset the loss of a significant retail customer. Despite this revenue growth, the company faced headwinds from declining anemia drug sales and the anniversary impact of losing a large retail customer. Gross profit margins improved due to stronger generic programs and fee-for-service agreements, while operating income also saw a healthy increase, reflecting effective cost management and operational efficiencies. The company continued its strategic capital allocation, including share repurchases and dividend payments, supported by robust liquidity and access to credit facilities.

Financial Statements
Beta

Key Highlights

  • 1Total revenue increased by 2% to $18.4 billion for the quarter, primarily driven by new customer wins and growth in the specialty segment (ABSG), partially offset by the loss of a major retail customer.
  • 2Gross profit margin improved by 5 basis points to 2.82% of total revenue, attributed to stronger performance in generic programs and fee-for-service agreements.
  • 3Operating income rose by 8% to $213.0 million, reflecting improved gross profit and effective management of operating expenses, though future growth will be impacted by a large customer contract renewal.
  • 4The company completed the acquisition of Innomar Strategies Inc., a Canadian specialty pharmaceutical services company, for $13.4 million, expanding its Canadian operations.
  • 5Diluted earnings per share from continuing operations increased by 20% to $0.42, benefiting from operating income growth, lower interest expense, and a reduced effective tax rate.
  • 6Liquidity remains strong, with significant availability under revolving credit facilities and a receivables securitization facility, providing ample capital for working needs and strategic initiatives.
  • 7The company repurchased $273.7 million of its common stock during the first nine months of fiscal 2009 as part of its ongoing share repurchase program.

Frequently Asked Questions